Clinical stage drug discovery and development firm Hepagene Therapeutics Inc. on Tuesday said it has garnered a total of $40 million in its Series B1 round led by ByteDance-backer Loyal Valley Capital.
Oceanpine Capital and existing investor Apricot Capital joined the round.
The company will use the proceeds to support the clinical research of pipeline candidates, it said.
Since its inception in 2016, Hepagene has been engaged in the therapy areas targeting liver diseases such as non-alcoholic steatohepatitis, chronic Hepatitis B infection and cancer.
Source: Hepagene Therapeutics, Inc.
